Sign in
WithdrawnEarly phase 1

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
Dec 2021
Ended
Jun 2024
Type of study
Interventional
Treatments tested
  • Selinexor
  • Dexamethasone
Record updated
17 November 2022
Why it stopped
Funding withdrawn

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Diagnosis of primary AL amyloidosis
  • Relapsed and/or refractory AL amyloidosis
  • Measurable disease
  • Male or female patients 18 years or older
  • Able to give voluntary written consent
  • Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2
  • Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3
  • Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
  • Calculated creatinine clearance ≥ 30 mL/min

Who cannot take part

  • Prior exposure to Selinexor
  • Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
  • Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy
  • Major surgery within 14 days before enrollment
  • Radiotherapy within 14 days before enrollment
  • Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort
  • Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • Participation in another clinical trials involving investigational agents within 30 days of starting this trial
  • Clinically significant cardiac disease
  • Severe obstructive airway disease
  • Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
  • Serious medical or psychiatric illness
  • GI disease or GI procedure that could interfere with the oral absorption or tolerance including difficulty swallowing
  • Female patients who are lactating or have a positive serum pregnancy test during the screening period
  • Non-AL amyloidosis
  • Clinically overt myeloma
  • Peripheral neuropathy (grade 2 with pain or grade 3 or higher)

Where in United States

  • Weill Cornell Medicine - Multiple Myeloma CenterNew York, United States

About the trial

What the trial wants to find out

The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.

The group in the trial

  • selinexor/ dexamethasone (Sd)Treatment being tested

    Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity Dexamethasone • 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23

    Treatment: Selinexor and Dexamethasone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 November 2022